Research ArticleOriginal Research
Teratogen Use in Women of Childbearing Potential: An Intervention Study
Karie A. Morrical-Kline, Alison M. Walton and Tracey M. Guildenbecher
The Journal of the American Board of Family
Medicine May 2011, 24 (3) 262-271; DOI: https://doi.org/10.3122/jabfm.2011.03.100198
Karie A. Morrical-Kline
PharmD
Alison M. Walton
PharmD, BCPS
Tracey M. Guildenbecher
MD

References
- ↵Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010; 121: e1–e170.
- ↵American Diabetes Association. Standards of Medical Care in Diabetes–2010. Diabetes Care 2010; 33(Suppl 1): S11–S61.
- ↵Buhimschi CS, Weiner CP. Medication in pregnancy and lactation. Part 1. Teratology. Obstet Gynecol 2009; 113: 166–88.
- ↵
- ↵
- ↵Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354(23): 2443–51.
- ↵US Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM053113/UCM053113. Accessed April 20, 2010.
- ↵Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008; 143: 169–236.
- ↵
- ↵US Food and Drug Administration. Summary of proposed rule on pregnancy and lactation labeling. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093310.htm. Accessed December 22, 2010.
- ↵Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–52.
- ↵Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat 23 2010; (29): 1–44.
- ↵Hamilton MB. SuperSurvey- Online Survey Response Rates and Times: Background and Guidance for Industry. Available at: http://secure.supersurvey.com/papers/supersurvey_white_paper_response_rates.pdf, Longmont, CO: Ipathia, Inc. 2009.
In this issue
Teratogen Use in Women of Childbearing Potential: An Intervention Study
Karie A. Morrical-Kline, Alison M. Walton, Tracey M. Guildenbecher
The Journal of the American Board of Family
Medicine May 2011, 24 (3) 262-271; DOI: 10.3122/jabfm.2011.03.100198
Jump to section
Related Articles
- No related articles found.
Cited By...
- Pregnancy protection and pregnancies in women prescribed ACE inhibitors or ARBs: a cross-sectional study in primary care
- Promoting Safe Prescribing in Primary Care With a Contraceptive Vital Sign: A Cluster-Randomized Controlled Trial
- Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study